a.okonkwo97/100
Cold chain intact. Phase-change pack solid at arrival, day 4. Declared and independent figures differ by less than repeatability.
SWB — Shanghai Wibson Biotechnology Co., Ltd.
Shanghai, CN · established 2019. The index holds 204 assay reports across 38 batches and 24 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where SWB sells
Shanghai Wibson Biotechnology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit SWB at shanghaiwibsonbiotechnology.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Shanghai Wibson Biotechnology Co., Ltd.
- Short code in this index
- SWB
- Also known as
- SWB · SWB Biotech · Shanghai Wibson Biotechnology
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 2019
- First record in index
- 16 Apr 2024
- Most recent record
- 01 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
17.2%
n=204
Retail, shipped to the buyer
71.1%
n=204
Direct to the laboratory
8.3%
n=204
Median courier leg, direct despatch
8d
n=17
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 35 | 17.2% |
| Retail purchase, shipped to the buyer | 116 | 56.9% |
| Retail purchase via a third-party forwarder | 29 | 14.2% |
| Supplier despatch direct to the laboratory | 17 | 8.3% |
| Laboratory retained-sample archive | 7 | 3.4% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 204 SWB records the index holds, 35 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 14 of the 24 compounds SWB is represented by here — IGF-1 LR3, Tirzepatide, Ipamorelin, P21, Retatrutide, CJC-1295 (no DAC) and 8 further compounds. Those are the SWB lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for SWB. 35 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is SWB's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where SWB despatched a sample direct to a laboratory, the courier leg ran a median 8 days across 17 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.95%
n=204
Interquartile range
0.98pp
n=204
10th percentile
97.78%
n=204
Pass rate vs index spec
99.0%
n=204
Median recovery vs claim
97.7%
n=125
Median water
4.72%
n=204
Median |mass error|
2.3ppm
n=176
Records carrying a flag
38.7%
n=204
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.80pp
n=26
Index median spread
0.67pp
n=28
Lots tested 3+ times
26
n=38
Across the 26 SWB lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.80 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.13pp
n=38
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
68%
n=38
Divergences beyond 1 pp
0%
n=38
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.96%
n=180
Supplier-supplied median
99.09%
n=17
Supplier-supplied share of records
8.3%
n=204
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of SWB batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
80/100
n=38
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 47% | 25 points | |
| Peptide content stated | 55% | 20 points | |
| Endotoxin stated | 26% | 15 points | |
| Named impurities rather than a total | 46% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 31 | 98.71 | 98.55 | +0.16 | 97.0 | 94 |
| Semaglutide | Incretin | 26 | 98.64 | 98.89 | -0.25 | 97.0 | 100 |
| Retatrutide | Incretin | 20 | 98.25 | 98.37 | -0.13 | 96.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 19 | 97.58 | 98.28 | -0.70 | 95.0 | 100 |
| 5-Amino-1MQ | Non-peptide | 13 | 99.34 | 99.45 | -0.11 | 98.0 | 100 |
| Ipamorelin | Growth-hormone | 13 | 99.61 | 99.47 | +0.14 | 99.0 | 100 |
| AOD-9604 | Metabolic | 10 | 99.35 | 99.29 | +0.06 | 98.0 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 8 | 99.20 | 99.09 | +0.11 | 98.0 | 100 |
| P21 | Neuroactive | 8 | 99.23 | 99.23 | 0.00 | 98.0 | 100 |
| CJC-1295 with DAC | Growth-hormone | 7 n=7 | 98.38 | 98.95 | -0.57 | 97.5 | 100 |
| L-Glutathione (reduced) | Short | 7 n=7 | 99.00 | 99.33 | -0.33 | 98.5 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 7 n=7 | 99.40 | 99.35 | +0.05 | 98.5 | 100 |
| MGF | Growth-hormone | 6 n=6 | 98.56 | 99.29 | -0.73 | 97.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 6 n=6 | 99.23 | 99.38 | -0.15 | 98.5 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 4 n=4 | 99.56 | 99.49 | +0.07 | 98.5 | 100 |
| BPC-157 | Tissue-repair | 4 n=4 | 99.38 | 99.16 | +0.22 | 98.0 | 100 |
| Exenatide | Incretin | 4 n=4 | 99.41 | 98.98 | +0.43 | 98.0 | 100 |
| Gonadorelin | Hypothalamic | 3 n=3 | 99.02 | 99.12 | -0.10 | 98.5 | 100 |
| Selank | Neuroactive | 2 n=2 | n<3 | 99.59 | — | 99.0 | 100 |
| Enclomiphene citrate | Non-peptide | 2 n=2 | n<3 | 99.44 | — | 98.5 | 100 |
| Cagrilintide | Incretin | 1 n=1 | n<3 | 98.69 | — | 96.5 | 100 |
| IGF-1 DES (1-3) | Growth-hormone | 1 n=1 | n<3 | 99.12 | — | 95.0 | 100 |
| Mazdutide | Incretin | 1 n=1 | n<3 | 98.14 | — | 96.5 | 100 |
| Thymosin α1 | Tissue-repair | 1 n=1 | n<3 | 99.40 | — | 97.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 2 | 14 | 97.87 | 96.85–99.93 | 6 |
| 2024-Q3 | 1 | 4 | 99.41 | 99.35–99.46 | 4 |
| 2024-Q4 | 2 | 7 | 98.51 | 98.30–99.93 | 1 |
| 2025-Q1 | 3 | 24 | 99.01 | 97.65–99.74 | 0 |
| 2025-Q2 | 7 | 48 | 99.19 | 97.95–99.93 | 38 |
| 2025-Q3 | 5 | 21 | 99.34 | 98.76–99.93 | 13 |
| 2025-Q4 | 6 | 34 | 98.22 | 96.81–99.39 | 10 |
| 2026-Q1 | 7 | 33 | 98.97 | 97.93–99.93 | 6 |
| 2026-Q2 | 4 | 10 | 98.47 | 98.22–99.93 | 1 |
| 2026-Q3 | 1 | 9 | 98.74 | 97.96–98.86 | 0 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 94 | 99.00 | +0.00 | 99.00 |
| PeptideMeter | 35 | 98.71 | -0.05 | 98.76 |
| Medutest | 29 | 99.02 | +0.08 | 98.94 |
| VendorInvestigate | 13 | 99.17 | -0.11 | 99.28 |
| Nordanalyt | 21 | 98.96 | +0.02 | 98.94 |
| Kestrel | 12 | 98.92 | +0.24 | 98.68 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
94.0/ 1001,038 ratings across the index network
h.vermeulen96/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Catalogue availability matched the published catalogue.
ai.krastev95/100
Reconstitution of sermorelin 5 mg: clear on contact, no haze, no particulate. Figures as reported by the named service. Not reproduced by the index.
a.pires99/100
Residual-solvent screen included unrequested. Research use. Not approved for human administration.
o.kirchner96/100
Certificate carries the gradient and the column chemistry. Complete against the index minimum data set at first issue. Identifier matches across vial, certificate and commercial documentation. Documentation practice, not a single purity figure, is the substance here.
k.mensa95/100
Declared figure not adjusted upward between certificate and commercial documentation. Supplementary certificate produced without demur.
n.solberg99/100
Release signed and dated, named individual. Declared and independent figures differ by less than repeatability. Record covers the lots named. Not generalised.
am.hartmann98/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. n=1, declared as n=1.
a.sandvik100/100
Tracking live from despatch, accurate at every scan, delivered on the quoted day. Evidence base adequate for a rating on this criterion.
r.kjaer98/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Tracking record corresponded to consignment position at every hop. Documentation practice, not a single purity figure, is the substance here.
b.baptista100/100
Water content on the certificate with the titration method stated. Identifier matches across vial, certificate and commercial documentation.
k.weiss100/100
Seven orders across eleven months, every one dispatched inside the quoted window. Declared and independent figures differ by less than repeatability.
b.bruun97/100
Fill uniformity: 8 units weighed against declared fill, all within 2%. Declared and independent figures differ by less than repeatability.
ca.lindholm98/100
Cross-check: Janoshik and VendorInvestigate, same lot, agreement to 0.1 points. Both agree with the declared figure. Catalogue availability matched the published catalogue.
al.villalobos99/100
Retention time assigned to the principal peak, printed. Technical response inside four hours, working day.
a.kaufmann95/100
Batch record supplied in full on request, attached rather than summarised. Tracking record corresponded to consignment position at every hop. Contributor declares no interest beyond the transaction.
r.nilsen96/100
Consistency: 10 lots, purity band under 1.0 points wide.
d.roos97/100
3 orders, 14 months. No substitution, no reformulation, no post-payment unavailability. Supplementary certificate produced without demur.
f.sorensen98/100
Water content by Karl Fischer, method named. Declared and independent figures differ by less than repeatability.
k.vermeulen99/100
Lot SWB-26-627 submitted to PeptideMeter. Declared 98.6%, reported 98.6%. Delta inside method repeatability. No further comment.
in.boateng98/100
Documentation complete at first issue. No supplementary request raised. Technical response inside four hours, working day. Record covers the lots named. Not generalised.
b.lundgren97/100
Counter-ion identity and content answered quantitatively, one working day. n=1, declared as n=1.
fr.villalobos95/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Identifier matches across vial, certificate and commercial documentation.
o.pereira99/100
Published stock status matched availability. Same-day dispatch. Supplementary certificate produced without demur. Independent verification of individual lots still required.
a.halonen100/100
Seven orders, phase-change pack on each, solid on arrival every time. Declared and independent figures differ by less than repeatability.
i.nwosu98/100
Direct-supply material 98.1%. Intermediary vial, same nominal description, 98.0%. Subsequent orders placed with the same supplier.
Block 12
Most recent records
Block 13
Contributor annotations on SWB records 358
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on SWB material are below, each linked to the record it sits on.
A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.
On compounds with a single supplier, independently purchased records are the only thing preventing the evidence base from being entirely supplier-generated. They matter disproportionately there.
Any covalent dimer would appear at roughly twice the parent mass, and on a cysteine-containing sequence at twice the parent minus two hydrogens. The envelope on this record shows no series at either offset.
Provenance handles supplier selection. It does not handle submitter selection, which is the larger confounder and the one the index cannot measure.
One retail vial is one draw from a fill. Two or three from the same lot would separate fill variation from lot quality, and that is the cheapest useful experiment in this whole field.
Instrument class is on the record, which is what allows -2.0 ppm to be read at its proper weight. The index distinguishes "confirmed" from "consistent with" precisely on this field.
Lot SWB-2511-Y7814 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.
The observed monoisotopic mass on this record reconciles with the theoretical value to four decimal places, which is the arithmetic the index re-derives in its own build check rather than accepting from the report.
Every annotation the index holds on SWB material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what SWB itself publishes, open shanghaiwibsonbiotechnology.net → alongside.
Block 14
Where to buy SWB
Shanghai Wibson Biotechnology Co., Ltd. sells direct from shanghaiwibsonbiotechnology.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the SWB store at shanghaiwibsonbiotechnology.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.